eTheRNA is an mRNA technology platform company with integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics. The company believes that customized LNPs are critical enablers in advancing mRNA technologies to new levels of prophylactic and therapeutic utility.
Role within EXPERT
- Therapeutic mRNA payload (WP3): eTheRNA has ample experience in the production of mRNA, including the production of GMP grade mRNA for clinical studies. eTheRNA will act as the supplier of high-quality mRNA for the whole consortium and will provide GMP grade TriMix mRNA to support the first-in-human study.
- Preclinical antitumor efficacy (WP10): eTheRNA has strong expertise in addressing the antitumor efficacy of mRNA immunotherapies in various preclinical tumor models. Besides addressing antitumor efficacy of lead formulations in murine models, eTheRNA will perform a thorough immune profiling of the lead mRNA formulation and unravel its mode of action.
- Clinical Study (WP11): eTheRNA has experience in running clinical studies with mRNA and in evaluating immune response data of patients participating in a clinical study with their lead candidate ECI-006.
Florence Lambolez, Principal Scientist Immuno-Onco, Internal Project Sponsor 1Email
Marina Cools, VP Clinical, WP11 lead, Internal Project Sponsor 2Email
Bernard Sagaert, Interim CEO, WP3 leadEmail
Stefaan De Koker, VP Discovery, WP10 leadEmail
Dirk Van Broekhoven, VP Corporate ManagementEmail
Brenda De Keersmaecker, Senior Scientist In Vitro Pharmacology, Internal Project Management EXPERTEmail